TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Combination of Diet and 5ASA ( 5-aminosalicylic Acid) for Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Informed consent~2. Established diagnosis of UC by the Paris classification and Revised Porto Criteria.~3. Age: 10 - 19 years (inclusive)~4. Mild to moderate active disease, 10 ≤ PUCAI ≤45~5. Extent E2-E4 by the Paris classification~6. Weight \>30 kg (ensures that patients who received 5ASA ≤2 grams are eligible)~7. Stable medication (IMM/ 5ASA) use or no change in medication use for the past 6 weeks. Patients who have received topical 5ASA therapy for \<10 days and are active may be included if topical therapy is stopped at enrolment.~8. Patients not receiving 5ASA or using 5ASA\<50mg/kg/day~Exclusion Criteria:~1. Any proven current infection such as positive stool culture, parasite or C. difficile.~2. Steroids (oral or intravenous) use in the past 3 months.~3. Patients who continue topical 5ASA or steroids after enrolment~4. Use of biologics in present or in past 6 months~5. Use of antibiotics for more than one week in the past 60 days~6. PUCAI \>45~7. Acute severe UC in the previous 12 months.~8. Current extra intestinal manifestation of UC.~9. Primary Sclerosing Cholangitis (PSC) or Liver disease~10. Pregnancy.~11. Vegans or patients unwilling or unable to consume eggs~12. Inflammatory Bowel Disease (IBD) unclassified~Exclusion criteria Comments:~1. Stool culture, parasite or C. difficile will only be measured if the patient has diarrhea.~2. Patients who have received treatment enemas for 3 weeks or less then 3 days and are active, can be included but must stop the enemas on the day of enrolment

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Control Diet 6 weeks of Oral 5ASA (standard recommended dosing 60-75 mg/kg/day; minimum 2.5, maximum 4 grams/day)+ Low residue diet and 6 more weeks of Oral 5ASA+ Free diet
- Group 2 (Type: EXPERIMENTAL): 6 weeks of Oral 5ASA (standard recommended dosing 60-75 mg/kg/day; minimum 2.5, maximum 4 grams/day)+ UC diet and 6 more weeks of Oral 5ASA+ UC diet stage 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Nortriptyline and Topiramate in the Initial Treatment of Vestibular Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~-Men and women aged 18 to 70 with untreated vestibular migraine variant as diagnosed by history.~Exclusion Criteria:~* Patients with allergies to nortriptyline or topiramate and their analogs or medication interactions that preclude their use.~* Patients under the care of a psychiatrist.~* Patients who are pregnant or trying to become pregnant.~* Patients taking more than 5 prescription medications.~* Patients with cancer.~* Patient has a history of immunodeficiency.~* Patient has a history of substance abuse within the preceding 6 months prior to screening.~* Patient has used an investigational drug or device in the the 3 months prior to screening.~* Patient is using marijuana for medical or other uses.~* Patient has any other clinically significant illness or medical condition that, in the investigator's opinion, would prohibit the subject from participating in the study.~* Patient with traumatic brain injury.~* Patients taking Nortriptyline, MAOIs~* Patients with liver or kidney dysfunction or glaucoma~Due to know drug interactions, patients taking the following medications will be excluded.~Nortriptyline: monoamine oxidase inhibitors (MAO) such as phenelzine. Patients on oral contraceptives will be asked to use a secondary method as nortriptyline can reduce the effectiveness of oral contraceptives.~Topiramate: acetazolamide (kidney stones), digoxin~Exclude subjects with liver dysfunction, kidney dysfunction and glaucoma (per the risks associated with topiramate).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- nortriptyline (Type: ACTIVE_COMPARATOR): If after four (4) weeks of diet modification, patients are still experiencing migraines, they may be randomized to nortriptyline for eight (8) weeks. If still experiencing symptoms, they will receive topiramate for eight (8) weeks.
- topiramate (Type: ACTIVE_COMPARATOR): If after four (4) weeks of diet modification, patients are still experiencing migraines, they may be randomized to topiramate for eight (8) weeks. If still experiencing symptoms, they will receive nortriptyline for eight (8) weeks.
- diet modification (Type: OTHER): Participants will begin with diet modification for four (4) weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* premenopausal women ≥ 18 years~* diagnosis of PCOS based on the recent 2006 Androgen Excess Society criteria (modified from Rotterdam 2003)~* waist circumference \>88 cm~* fasting TG 2.0 - 5.0 mmol/L~* stable on any type of oral contraceptive for a minimum of 3-months~Exclusion Criteria:~* known contraindications for MRI~* pregnancy, lactation, desire to become pregnant~* participation in another clinical trial~* fasting TF level ≥ 5.0 mmol/L~* AST or ALT \> 2.5 times upper limit of normal (ULN)~* creatinine kinase (CK) \> 6x ULN~* creatinine \> 115 μmol/L~* fasting glucose ≥ 7.0 mmol/L and/or 2h glucose post oral glucose tolerance test (OGTT) ≥ 11.1 mmol/L or personal history of DM2~* personal history of renal disease, liver disease (except NAFLD), or heart disease~* body mass index (BMI) \< 18 or \> 40 kg/m²~* increased alcohol use (\>9 standard drinks per week \[standard drink = 12oz beer, 5oz wine, or 1.5oz spirits\]) or drug use~* use of other hormonal contraception, growth hormone, glucocorticoids, anti-diabetic/anti-dyslipidemia medications, or anabolic steroids.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): fenofibrate 200mg/daily for 6 months
- 2 (Type: PLACEBO_COMPARATOR): Placebo match for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Part A~* Patients with any previously treated solid tumor-type other than hepatocellular carcinoma or intrahepatic cholangiocarcinoma that is advanced, or recurrent and progressing since last anti-tumor therapy, and for which no alternative, standard therapy exists.~* Prior chemotherapy, radiation therapy or immunotherapy must have been completed at least 4 weeks prior to the administration of the first dose of study drug, and patient has recovered~Part B:~* Patients with Non-small Cell Lung Cancer (NSCLC) or other protocol specified solid tumors with locally advanced or metastatic, non-resectable disease, which has progressed despite treatment with first-line standard of-care treatment, or first- and second-line treatment, dependent on expansion cohort.~* Prior therapy must have been completed 2-4 weeks prior to the administration of the first dose of study drug as specified per protocol according to type of prior therapy~Exclusion Criteria:~* Patient previously had known immediate or delayed hypersensitivity reaction or idiosyncrasy to the excipients~* Part A: Treatment with any PD-1, or Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 directed antibody, or with any other immunotherapy within 4 weeks prior to initiation of the study drug.~* Part A: Use of other biological investigational drugs (drugs not marketed for any indication), including use of investigational drugs targeting CD137/4-1BB within at least 5 half-lives (or within 8 weeks, whatever is longer) prior to the administration of the first dose of study drug.~* Part B: As defined per protocol for each expansion cohort, has not been treated with specified first/second-line standard-of-care therapies biological drugs (marketed or investigational) for treatment of the current cancer, or has not adequately recovered from AEs that occurred with prior therapy.~* Patient has an active autoimmune disease or a documented history of autoimmune disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NM21-1480 Treatment arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessing Outcomes in ED Patients With RV Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients \> 18 years old,~* with a non-significant CTPA scan (i.e. no acute disease), dyspnea PLUS an emergency physician performed echocardiogram with isolated RV failure OR CTPA scan with evidence of pulmonary hypertension OR comprehensive echocardiogram within 3 months of index hospital visit showing isolated RV dysfunction~Exclusion Criteria:~* Currently being evaluated and/or treated for RV failure or PH,~* those unable to have a comprehensive echocardiography performed,~* those with indeterminate RV function OR LV dysfunction on comprehensive echocardiography, and~* those patients with circumstances where they may be lost to follow-up (homeless, prisoner, severe psychiatric disorder, no reliable contact information).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clinical Pathway Cohort (Type: ACTIVE_COMPARATOR): Patients with isolated RV failure will be evaluated and managed in a specialized cardiovascular clinic.
- Standard Care (Type: NO_INTERVENTION): Patients with isolated RV failure will receive standard care and follow up.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Dilute Versus Concentrated Heparin for CRRT Anticoagulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years~* Renal failure, electrolyte disturbance, or volume overload requiring continuous venovenous hemodialysis (CVVHD) as determined by the Nephrology consult service~Exclusion Criteria:~* Age less than 18 years~* Active bleeding~* Coagulopathy as defined by baseline INR \> 1.8, aPTT \> 45 seconds, or platelet count \< 50 thousand/μL~* Active administration of systemic anticoagulation (such as warfarin, therapeutic unfractionated heparin, or therapeutic enoxaparin)~* Contraindication to heparin (allergy, thrombocytopenia with platelet count \< 50, known or suspected heparin induced thrombocytopenia \[HIT\])~* Contraindication to systemic anticoagulation (recent surgical or other invasive procedure, significant bleeding disorder, concern for intracranial bleeding, or other contraindication as determined by treating physician)~* Administration of drotrecogin (Xigris™)~* Anticipated surgical or other invasive procedure that would necessitate withdrawal of anticoagulation within 72 hours~* Expected termination of continuous renal replacement therapy (CRRT) or death in \< 24 hours~* The need for more than 500 cc an hour of IV fluids delivered proximal to the filter for the purpose of performing continuous venovenous hemofiltration (CVVH) or continuous venovenous hemodiafiltration (CVVHDF)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dilute heparin (Type: ACTIVE_COMPARATOR): Arm A will receive dilute heparin delivered as an intravenous infusion proximal to the dialysis filter.
- Standard concentrated heparin (Type: ACTIVE_COMPARATOR): Arm B will receive standard concentrated heparin and will be delivered as an intravenous infusion proximal to the dialysis filter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Regenerative Ability of TAMP BG and BD in Pulpotomized Primary Teeth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children free of any systemic disease or special health care needs.~* Children not receiving any anti-inflammatory medication.~* Cooperative children (positive/ definitely positive) according to Frankl's behavior rating scale.~* Restorable teeth.~* Teeth with vital carious pulp exposure that will bleed upon entering the pulp chamber and not requiring more than 5 minutes to achieve hemostasis after coronal pulp amputation.~* Teeth indicated for extraction for orthodontic purposes with the previously mentioned criteria (required for a subgroup for assessment of histological and inflammatory response outcomes).~Exclusion Criteria:~* Teeth with clinical or radiographic signs of pulp degeneration.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- TAMP bioglass (Type: EXPERIMENTAL): Tailored amorphous multiporous bioglass (TAMP-BG) of 70% SiO2 / 30% CaO was prepared according to Wang et al. (2011, 2013) in the tissue engineering lab, Faculty of Dentistry, Alexandria University as follows: Scaffolds were grounded to 180- to 300-μm particle size and sterilized at 180°C for 2 hours. The resulting powder was mixed with distilled water to obtain a putty like consistency that was carried to the pulp chamber and condensed lightly on the pulp stumps.
- Biodentine ™ (Type: ACTIVE_COMPARATOR): Biodentine ™ (BD) pre-dosed capsule were gently tapped on a hard surface to diffuse the powder. Five drops of the liquid from the single dose dispenser were poured into the capsule and mixed for 30 seconds at 4,200 rpm in an amalgamator according to manufacturer's instructions to obtain putty- like consistency. (Powder-liquid system). It was then be carried to the pulp chamber and condensed lightly on the pulp stumps. Final restoration was applied after 12 minutes, allowing Biodentine ™ to set.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Improving the Pregnancy Rate With Endometrial Sampling Before Intrauterine Insemination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All women undergoing superovulation with gonadotrophins and intrauterine insemination.~2. All women with cervical factor, mild male factor and/or unexplained infertility.~3. At least one patent Fallopian tube.~Exclusion Criteria:~1. Bilateral tubal disease~2. Severe male factor infertility~3. Intrauterine pathology (submucosal fibroid, endometrial polyp, adhesions)~4. Women with positive cervical culture and/or acute vaginal infection

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): Group 1 patients will receive standard superovulation-IUI treatment without endometrial sampling
- 2 (Type: ACTIVE_COMPARATOR): Group 2 patients will receive standard superovulation-IUI treatment with endometrial sampling performed in the preceding cycle. It will be done in the follicular phase not later than day 10 of the cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients whose legal representatives can provide informed consent (Informed consent from the patients where possible).~* Patients who satisfy both of the following diagnostic criteria:~  * Diagnosis of major neurocognitive disorder due to Alzheimer's disease according to Diagnostic and Statistical Manual of mental disorders (DSM-5)~ * Diagnosis of probable Alzheimer's disease according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)~* Hospitalized patients or care facility patients~* Patients with an Mini-Mental State Examination (MMSE) score of 1 to 22~Exclusion Criteria:~* Patients with complications of dementia or memory impairment other than Alzheimer's type dementia~* Dementia patients with a Modified Hachinski Ischemic Score of 5 or higher~* Patients with psychological symptoms or behavioral disorders that are clearly due to other medical conditions or substances~* Patients with a complication or history of stroke or transient ischemic attack, except for asymptomatic stroke~* Patients with heart failure classified as New York Heart Asscoiation (NYHA） III or IV~* Patients who require drug therapy for arrhythmia or ischemic heart disease~* Body weight of less than 30 kg~* Patients with a high risk of suicide~* Patients with a complication or history of seizure disorder~* Patients with a complication or history of neuroleptic malignant syndrome, tardive dyskinesia, paralytic ileus, or rhabdomyolysis~* Patients with thyroid disease (except if the disease has been stabilized with drug therapy for 3 months or longer prior to time of informed consent)

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Aripiprazole, 2 mg/day (Type: EXPERIMENTAL): None
- Aripiprazole, 3 mg/day (Type: EXPERIMENTAL): None
- Aripiprazole, 6 mg/day (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Dexmedetomidine Dose on Motor Evoked Potentials

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing multi-level posterior spine fusions requiring motor evoked potential monitoring~Exclusion Criteria:~* Allergy to dexmedetomidine, propofol~* Conditions knows to make recording of motor evoked potentials difficult, including poorly controlled diabetes, severe peripheral neuropathy, severe myelopathy, or previous surgery during which motor evoked potentials were difficult to obtain~* Hepatic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- High dose dexmedetomidine (Type: EXPERIMENTAL): Patients will receive dexmedetomidine 0.5 mcg/kg/hr plus propofol 50 mcg/kg/min
- Low dose dexmedetomidine (Type: ACTIVE_COMPARATOR): Patients will receive dexmedetomidine 1.0 mcg/kg/hr plus propofol 25 mcg/kg/min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* TTP with platelets less than 100,000 and microangiopathic hemolytic anemia~* Age greater than 18 and less than 60~* LDH \> 2x upper limit of normal~* PT and PTT normal~* Patients must give signed informed consent~* Pre-menopausal woman must have negative pregnancy test.~* TTP not related to underlying cancer, treatment of cancer or transplantation.~* TTP not associated with drugs.~Exclusion Criteria:~* LFTs AST/ALT \> 2x upper limit of normal~* Hepatitis B and Hepatitis C infection.~* HIV with active opportunistic infections~* Acute or chronic Disseminated Intravascular Coagulation (DIC), defined as D-dimer 8ug/ml and fibrinogen\<100 mg/dl~* TTP related to drugs, malignancy and transplantation.~* Pregnancy~* Concurrent other investigational drug use during this study.~* Porphyria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Danazol, Plex, Steroids (Type: EXPERIMENTAL): Everyone will receive Danazol with plasma exchange and corticosteroids
- Historic Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues